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MicellesPoly(1-vinyl-2-pyrrolidone) (Povidone, PVP) is one of the most interesting and versatile synthetic polymers
utilised in the pharmaceutical and cosmetic industries. Its large-scale commercial production offers an assort-
ment of products in a wide range of molecular weights but poorly-controlled (macro)structural parameters
(i.e., dispersity, functionality) limiting the efficiency of PVP-based drug delivery systems (DDS). In this work, syn-
thesised linear and star-shaped PVPs with a strictly defined structure and functionality were compared with the
linear, commercially-supplied product and explored as potential vehicles for physical entrapment of metronida-
zole (MTZ). Here, a question is addressed how differences in their macromolecular properties affect the
amorphisation of MTZ, drug encapsulation, the stability of drug-loaded micellar structures and their in vitro re-
lease from the carrier. TheX-ray diffraction studies and calorimetricmeasurements revealed thatMTZ crystallises
in all investigated herein systems reducing the glass transition temperature of the binary mixture significantly.
Transmission electron microscopy and dynamic light scattering analysis revealed that MTZ-loaded DDS are
able to form ultrasmall regular nanocarriers with an increasing effect of regularity and sphericity from star-
shaped DDS to linear-based ones. We founded that synthesised linear-based DDS is the most effective for MTZ
entrapment (PVP:MTZ=1:1 weight ratio) due to their smallest hydrodynamic radius dh= 14.7 nm, the highest
stability ofmicellar structures−2.37mV, and the highest values of loaded drug 76.5%.Moreover, all applied PVP-
based DDS revealed an initial burst release effect of MTZ (pH = 7.4) reaching up to 60% of drug released within
the first 5 h (the first-order release model fits). The marked efficiency of MTZ-loaded DDS of strictly defined
structural parameters indicates the great importance of polymer preparation strategy in the targeted therapy.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Polymeric materials have received increasing attention as new addi-
tives for drug formulations and drug delivery systems (DDS) [1,2]. The
most desirable are non-toxic, biocompatible/biodegradable macromol-
ecules of tailor-made parameters (i.e., those characterised by targeted
molecular weight, Mn, lowmolecular weight distribution –Đ dispersity,
preserved chain-end fidelity) produced via various kinds of controlledhysics, University of Silesia in
),
nski@smcebi.edu.pl
.V. This is an open access article undradical polymerisation methods (CRP). Due to their unique properties,
polymeric vehicles can modify the way the drug is solubilised, distrib-
uted and transported into the organism. In fact, there aremanydifferent
ways of using polymers to enhance drug bioavailability [3]. The most
common ones include preparation of physical mixtures or solid disper-
sions that affects the degree of crystallinity, physical state, and thermo-
dynamic properties of active pharmaceutical ingredients (APIs) leading
in consequence to the improvement of their pharmacokinetic parame-
ters [4]. Recently, micellar/microspherical polymeric (nano)carriers
attracted special attention, since they not only enable the encapsulation
of poorly soluble hydrophobic substances what increases their bioavail-
ability but also affects API's release at specific molecular targets. Note-
worthy, by a simple modification of the composition and topology
of polymeric matrices, it is possible to design DDS for long-term drug
release [5,6].er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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for improvement for micellar-based formulations that in majority cases
do not bring satisfactory therapeutic effects. As a consequence, themod-
ification of existing solutions and designingnovel ones are of key impor-
tance in pharmaceutical and biochemistry scientific/industrial fields. In
this way, a change of both, forms of drugs (i.e., production of salts/es-
ters, amorphisation) and polymeric matrices (composition, topology),
has been systematically investigated [7]. Notably, searching formore ef-
ficient DDS, providing a faster dissolution and enhanced bioavailability,
is particularly important for APIs that to date have formed only a fewde-
vices to sustainably drug delivery. One of them is metronidazole (MTZ)
gaining interest due to its great antibacterial activity, especially because
of its use as a medicine for a lifestyle disease, such as gastric ulcers
caused by the infection with H. pylori. It needs to be emphasised that
some of the few attempts of MTZ releasing DDS consisted of chitosan
[8], silica/polydimethylsiloxane/calcium xerogels [9], Eudargit-
carrageenan mixtures [10], or even hydrogels based on crosslinked
polymethacrylates [11] and poly(1-vinyl-2-pyrrolidone) (PVP) [12].
An interesting solution seems to be the use of polymer microspheres,
which ensure gastric retention of the drug and, additionally, slow
down its release due to the necessity of prior degradation of the carrier.
Among this type of drug delivery systems, some attempts have been
made with the use of alginate [13] or chitosan and esterified cellulose
mixtures [14].
Inspired by these strategies, here we proposed and developed an-
other kind of drug carriers based on polymeric micelles, and demon-
strated it as an efficient vehicle for MTZ. As a model polymeric matrix,
PVP, approved for the internal use by the Food andDrug Administration
(FDA) [15] has been selected. Note that due to its widespread commer-
cial availability,many different applicationswere found for this polymer
as a drug carrier, starting from electrospun, drug-coated dressings for
transdermal delivery [16–18], bioconjugates with different APIs
[19,20] or peptides [21], nanostructured API-polymer composites [22]
ending to hydrogels with chitosan [23] or pectin [24]. Interestingly, de-
spite such a huge and increasing demand for PVP, its large-scale synthe-
sis upon uncontrolled polymerisation allows the production of poorly
defined macromolecules (lack of control over Mn and Đ). Although sig-
nificant progress has been made on a laboratory scale due to the use of
CRPmethods to 1-vinyl-2-pyrrolidone (VP) polymerisation (mainly the
reversible addition-fragmentation chain transfer, RAFT), the synthesis
of the well-defined linear and star-shaped PVP of Mn > 40 kg/mol re-
mains a challenge for modern macromolecular science or industry
[25,26]. Interestingly, the implementation of the methodology based
on high-pressure (HP) offered a unique opportunity to reduce/elimi-
nate limitations of ambient-pressure strategies, making it possible to
obtain higher molecular weight PVP of linear and star-shaped topology,
characterised by much better structural parameters than the commer-
cial material [27,28].
Here, having the well-defined linear and four-arm star-shaped PVP
produced via ‘green’ catalyst- and solvent-free HP strategies, we set
out to check, whether the matrix topology can influence the ability to
drug encapsulation (leading to API's amorphisation), the stability of
drug-loaded structures, and ability to effectively release the drug from
the carrier. Another aspect worth investigating is the difference in the
ability to solubilize the drug, and its releasing between two linearmatri-
ces obtained by different polymerisation strategies (controlled, solvent-
free vs commonly used uncontrolled solvent-assisted). Investigated
herein micellar DDS were prepared via solvent evaporation method
using different PVP-MTZ weight ratios. Differential scanning calorime-
try (DSC) and X-ray diffraction (XRD) measurements were carried out
to characterise the thermal and structural properties of the produced
formulations. Size and self-assembly of obtained DDS were examined
using dynamic light scattering (DLS) and transmission electron micros-
copy (TEM). The drug loading content (DLC) and drug release studies
(in phosphate buffer solution pH = 7.4) were performed through UV-
VIS spectroscopy.2
2. Materials and methods
Commercially available poly(1-vinyl-2-pyrrolidone) K90,
Dulbecco's phosphate-buffered saline (modified, without calcium chlo-
ride and magnesium chloride) were purchased from Sigma Aldrich.
Methanol was obtained from Chempur. MTZ was bought from Sigma-
Aldrich. Linear and star-shaped PVPs were obtained according to the
previously described method [28,29].2.1. Drug loading and micelle preparation
PVPs and MTZ were dissolved in methylene dichloride CH2Cl2 (or
chloroform, depending on polymericmatrix solubility) with the follow-
ing polymer/drug weight ratios: 2:1, 1:1 and 1:2 similarly to previously
reported procedures [30–36]. Solutions were added dropwise into
deionised water and stirred overnight to evaporate the organic solvent.
An excess of not encapsulated drug was removed via filtration (follow-
ing by the use of syringe filters). Next, aqueous solutions were
lyophilised. The absence of organic solvent in both empty and drug-
loaded micelles was confirmed via NMR and FT-IR analysis (please see
Supplementary Information). DLC was calculated from the following
equation: DLC ¼ mDMmDLM  100%, where mDM is the amount of drug in mi-
celles, while mDLM- the amount of drug-loaded micelles.2.2. Drug release studies
Polymer-drug systems (2mg)were dissolved in Phosphate-buffered
saline (PBS) pH= 7.4 (1.0 mL). The solutionwas introduced into a dial-
ysis cellulosemembrane bag (MWCO 3.5 kDa), whichwas placed into a
glass vial with 30mL of PBS and stirred at 37 °C in a water bath. The di-
alysis was carried out for 30 h. The buffer solution samples (100 μL)
were taken from the release medium at appropriate time intervals and
dissolved in methanol (1 mL) to determine the concentration of re-
leased drug by UV–Vis spectroscopy.2.3. Gel permeation chromatography
Molecularweights (Mn) and dispersity indices (Ð)were determined
by size-exclusion chromatography (SEC, Agilent Technologies, Santa
Clara, CA, USA) equipped with an 1100 Agilent 1260 Infinity isocratic
pump, autosampler, degasser, thermostatic box for columns, and differ-
ential refractometer MDS RI Detector. Addon Rev. B.01.02 data analysis
software (Agilent Technologies, Santa Clara, CA, USA) was used for data
collecting and processing. The SEC calculated molecular weights were
based on calibration applying linear polystyrene standards (Mp =
580–1,390,000 g/mol). Pre-column guard 5 μm (50 × 7.5 mm) and
two columns: PLGel 5 μm MIXED-C (300 × 7.5 mm) and Malvern
Visocotek T6000M (300 × 8 mm) were used for separation. The mea-
surements were carried out in DMF (HPLC grade) as the eluent contain-
ing 10 mM LiBr, at T = 40 °C with a flow rate of 0.8 mL/min.2.4. Differential scanning calorimetry
Calorimetric measurements were carried out by using a Mettler-
ToledoDSC apparatus equippedwith a liquid nitrogen cooling accessory
and anHSS8 ceramic sensor (heatflux sensorwith 120 thermocouples).
Temperature and enthalpy calibrations were performed by using in-
dium and zinc standards. The samples were prepared in an open alu-
minium crucible (40 μL) outside the DSC apparatus. Measurements
were performed in the temperature range from 200 K to 450 K at a con-
stant heating/cooling rate of 10 K min−1. Each measurement at a given
temperature was repeated 3 times. For each experiment, a new sample
was prepared.
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X-ray diffraction studies were performed using Rigaku Denki D/Max
Rapid II diffractometer equipped with a rotating silver anode, an inci-
dent beam (002) graphite monochromator and an image plate as a de-
tector in the Debye-Scherrer geometry. The diffraction patterns for neat
PVPs, MTZ and PVP-MTZ mixtures were collected 1 day after mixture
preparation, at 293 K. The samples were measured in glass capillaries
of 1.5 nm diameter. The beam size on the sample was 0.3 mm. The
background intensity from the empty capillary was subtracted, and
two-dimensional diffraction patterns were converted to the one-
dimensional function of the diffraction intensity vs the scattering vector
Q ¼ 4πsinθλ , where 2θ is the scattering angle and λ = 0.56 Å is the wave-
length of the incident beam.
2.6. Dynamic light scattering and zeta potential measurements
Hydrodynamic diameters (dh) and zeta potentials (ZP) of polymer
particles were measured onMalvern Zetasizer Nano-ZS (4mWHe\\Ne
ion laser, λ = 633 nm) for samples in deionised water (0.5 mg/mL) at
25 °C ± 0.1 °C.
2.7. Transmission electron microscopy
Micelles were visualised by high-resolution transmission electron
microscope (TEM, FEI Tecnai G2 Spirit BioTWIN) at 120 kV. The polymer
samples in deionised water (0.5 mg/mL) placed on the carbon-coated
copper grids (200-mesh) were dried for 2 h.
2.8. UV–Vis spectrophotometry
The measurements by UV–Vis spectrophotometry (Hitachi U-1900)
were performed for the samples in methanol. Concentrations of MTZ
were calculated based on the calibration curve (please see SI, Fig. S5).
2.9. Critical micellisation concentration
Critical micellisation/aggregation concentrations (CMC/CAC) for all
polymers were carried out employing the pendant drop method of sur-
face tension determination on the Kruess DSA 100S goniometer.
3. Results and discussion
Within this work, we selected three different PVP matrices i) linear
(MnSEC = 66.2 kg/mol; Đ = 1.48) produced via HP thermally-induced
free-radical polymerisation, ii) unique, four-arm star-shaped PVP
(MnSEC = 175.6 kg/mol; Đ = 1.81) synthesised via HP RAFT [28] that
was previously not used as potential drug carrier, and iii) commercially
supplied PVP (commercial name K90; MnSEC = 108.6 kg/mol; Đ =
1.78), which were applied as polymeric support for MTZ. Both synthe-
sised linear and star-shaped polymers were characterised by well-
defined structural parameters including relatively moderate
dispersities, high chain-end fidelity and importantly, high purity,
which resulted from the application of metal-free and solvent-free syn-
thetic strategies. On the other hand, the commercial PVP exhibited
moderate dispersity and consisted of macromolecular chains of both
long and short length probably due to the uncontrolled large-scale
synthetic procedure (aqueous solution process in the presence of
H2O2 as a starter and free metal ions) [37]. The glass transition temper-
ature, Tg, of star-shaped PVP, was significantly lower compared to the
linear one (Tg= 429 K vs Tg= 443 K) despite their almost twice higher
Mn, which is consistent with other literature data of non-linear poly-
mers (more compactness, lower intrinsic viscosity) [29,38]. Interest-
ingly, higher Tg value (Tg = 450 K) of commercial PVP probably
resulted from antiplasticizing effect of the polar solvent used in the3
polymerisation process that was previously reported by some of us
[28] and other researchers [39]. It is hypothesised that both difference
in matrices composition/topology and thermodynamic parameters can
be attributed to varied ability to drug encapsulation, micellar structure
stability, their hydrodynamic diameter values and drug release profiles.
Empty (blank)micellar structures and drug-loaded ones were prepared
via direct dissolution in an organic solvent (chloroform) following their
removal via evaporationwith subsequent freeze-drying. It is worth not-
ing that such a preparation pathway was selected as the most suitable
for studied herein systems (PVP: metronidazole binary mixtures),
among other common methods, including direct dissolution in water
or dialysis. Our choice was dictated by the fact that selected herein
PVPmatrices differed in topology and slightly in composition (the pres-
ence of sulfur-based core in star-shaped PVP), which affected their
water solubility. In turn, the dialysismethod appears to be less advanta-
geous for our systems from the viewpoint of loading a potentially small
amount of drug and forming polymer aggregates in the micellization
process, which could facilitate the removal of API from self-assembling
micelles. Noteworthy, the choice of micellization strategy can signifi-
cantly influence both the drug encapsulation efficiency and micellar
structure parameters (their size and polydispersities). Basically, the lat-
ter parameters are affected by the concentration of the polymeric ma-
trix, the nature of the applied organic solvent, and the order of
solvents addition. Thus, to investigate the impact of the selected PVP
matrix onmicelle formation and properties of producedmicellar super-
structures (empty and drug-loaded),micellizationwas performed using
standardized method (direct dissolution in organic solvent) and con-
stant concentration of polymeric matrix for all systems. In this context
it is worth to remind that the same micellization strategy (the solvent
evaporation)was already employed for other PVP containing polymeric
carriers. [40,41] Although one of the main drawback of this strategy is a
necessity of using a toxic solvent; further, NMR and FT-IR analyses of
prepared herein formulations clearly indicated that organic solvent
has been completely evaporated making this concept acceptable from
a biomedical point of view.
Initially, as one of the most significant parameters for the prepara-
tion of micellar-based DDS, the critical micellisation/aggregation con-
centration (CMC/CAC) has been estimated. Note that above CMC/CAC
polymeric materials containing amphiphilic domains are expected to
arrange in aqueous solutions by self-assembly. Its value can change dra-
matically with the variation, e.g., in the polymer topology and chain
length (through the steric effects) as well as the presence of polar do-
mains (structural effects). Literature data report that the CMC/CAC de-
creases with the elongation in alkyl chain length, which favours the
insoluble domain [42]. This phenomenon can be observed for linear
and commercial samples (higher Mn = 108 kg/mol – lower CMC =
0.04 mg/mol) (see Fig. 1). On the other hand, referring to the linear
and star-shaped samples obtained via HP solvent-free strategy, the
star-like PVP showed lower CMC value (although their Mn is higher
than the linear one), which may be an effect of the higher density of
PVP segments (compactness) rendering easier the self-assembly pro-
cess. Therefore, it was found that star-like polymers are more prone to
form micellar structures and aggregates than linear ones, which is in
line with the other literature findings [43].
The resulted micellar and drug-loaded structures were evaluated
considering particle sizes, zeta potential (ZP) and drug loading capacity
(DLC). We are aware that from the pharmaceutical point of view the
most useful/optimal formulations assume a significant excess of the
polymeric matrix to the drug. Nevertheless, in our research, apart
from the formulation with an excess of the matrix to the MTZ (2:1),
we also tested two other systems, i.e., with the lower matrix concentra-
tion (1:2) and those with the same concentration of drug and matrix
(1:1). In this way, we can get a comprehensive insight into assessing
the impact of various formulations on the above-mentioned parame-
ters. Note that similar strategy was also employed in other studies
concerning drug-loaded micellar carriers [30–36].
Fig. 1.Determination of CMC/CAC bymeasuring the surface tension of a serial dilutions A) star PVP (0.05mg/mL), B) linear PVP (0.10mg/mL) and C) commercial PVP (0.04mg/mL). Solid
lines are the best linear fits in the two ranges of concentrations. From the change in the slope of γ vs log c, a critical micellisation concentration has been determined.
Table 1
Sizes of micelles (from DLS studies) and ZP of the examined systems.
PVP Unloaded
polymer

















star-shaped 16.68 −3.74 23.73 −16.4 21.6 −5.88 14.7 −17.1
linear 29.26 −7.5 14.22 +0.77 14.71 −2.37 14.6 −5.82
commercial – – 13.1 −2.13 30.64 −11.3 25.28 −3.5
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small hydrodynamic diameters (dh) in aqueous solutions. It seemed
that star-shaped PVP micelles showed both the smallest size and ZP
compared to linear systems, which is a typical phenomenon observed
for micelles formed by non-linearmacromolecules. After drug encapsu-
lation, thedh diameters and ZP of DDShave changed significantly. As ex-
pected, the weight ratio of PVP to MTZ strongly affects these
parameters. The explanation for these results lies in the differences in
solubility of both polymeric matrices and the drug as well as the degree
of drug dispersion in the PVP matrix. It should be emphasised that theFig. 2. Drug loading content values for different PVP-MTZ weight ratios for A
4
more soluble systems provided more homogenous dispersion of poly-
mers, and thus smaller, more stable micelles. Contrary, in less soluble
systems, the micellisation process-induced irregular aggregation of
PVP matrices and provided destabilisation of micellar systems. It can
also be noted that for all formulations decreasing ZP with increasing
MTZ loading suggests weaker stability of the prepared systems (their
tendency to aggregation is much higher).
The findings mentioned above also strongly affected the content of
the loaded drug. As presented in Fig. 2, at the weight ratio of PVP to
drug equal to 1:1, the highest DLC value 76.5% has been noted for linear
PVP-basedDDS,whereas systemsbased on star-shaped and commercial
PVP revealed similar values of the encapsulated drug (58.5% and 54.5%,
respectively). Additionally, for all three systems having higher polymer
concentrations (2:1), the lowest DLC values were obtained. Surpris-
ingly, the PVP: MTZ = 1:2 system based on commercial PVP exhibited
90% drug loading (Fig. 2C). However, in this case, drug loading efficiency
was the lowest of all the studied systems. It seems that this unexpected
scenario resulted from lower water solubility of commercial PVP (at
least one of fractions differing in Mn) that was also further reduced by
the presence of the polar drug leading to their precipitation. Thus, it
can be assumed that the commercial polymer shows little or no suitabil-
ity for use as a drug carrier.) star-shaped polymer, B) linear polymer and C) commercial polymer.
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DDS using TEM. Interestingly, as it can be seen in Fig. 3, the presence of
MTZ seems to force the polymer to self-assembly into spherical mi-
celles. In turn, neat, unloaded PVP polymers form irregular, flocculant
aggregates, much smaller than the micelles. Such results might suggest
that, at least in the solutions, loaded drugmigrates to the core of formed
particles and is surrounded by polymer chains. Additionally, linear PVP
creates more regular particles than the star-shaped PVP (please com-
pare Fig. 3B vs E). The particles revealed by TEM exhibit larger sizes
than those determined by DLS measurements. This discrepancy could
be due to the effect of sample preparation for TEM. The evaporation of
solvent may drastically increase the concentration of the material and
thus cause the aggregation/formation of larger particles. Moreover,
such results correspond with the relatively low ZP values suggesting
that particles formed in solutions are prone to aggregate when chang-
ing/increasing the concentration.
At this point, it needs to be stressed that among all micellar DDS
studied herein the most effective for physical entrapment of MTZ are
linear oneobtained via CRP (PVP:MTZweight ratio=1:1) characterised
by the lowest hydrodynamic radius of (dh = 14.7 nm), the highest con-
tent of the loaded drug (76.5%) and importantly, the highest stability of
produced nanoparticles (ZP = 2.37 mV). Of particular note is that the
linear PVP-based DDS has been prepared via HP polymerisation, ensur-
ing the control over polymer (micro)structural parametersFig. 3. TEM images of A) unloaded linear PVP, B) linear PVP loaded with MTZ (1:1 ratio), C) deg
E) star-shaped PVP loaded with MTZ (1:1 ratio). Bar = 100 nm.
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(i.e., dispersity, functionality). These systems presented nearly mono-
disperse structures of polymeric chains that in consequence, allowed
for the generationof vehicles of uniform, tuneable andhighly stable par-
ticles. The implementation of commercial PVP as MTZ carriers yields
less-stable nanoparticles (ZP = -11.3 mV) characterised by less regular
shapes, probably due to their poorly-defined macromolecular parame-
ters (see Table 1). Besides, their preparation via solvent-assisted meth-
odology could affect the lower DLC value (54.5% at PVP:MTZ weight
ratio = 1:1). It is related to the higher content of polar solvent mole-
cules entrapped into polymeric chains. Interestingly, star-shaped
matrices also prepared by solvent-free HP CRP methodology were
able to encapsulate slightly higher (58.5%) but much lower content of
the drug in comparison to the commercial and the linear PVP systems,
respectively. DDS composing of star-shaped PVP also showed more
stable micellar structures (ZP = -5.88) than those formed by the
commercially-supplied PVP.
In the next step, the studied MTZ and obtained polymer-drug
mixtures were characterised by DSC to probe their thermal properties
aswell as phase transitions, see Fig. 4. The heating of the neat crystalline
API revealed the presence of one clear endothermic process, melting,
occurring at Tm = 436 K, see the inset in Fig. 4A. Nevertheless, it
should be mentioned that as the studied MTZ is cooled down, it
crystalised at the applied standard cooling rate, 10 K min−1. This indi-
cates that it has an extremely low glass-forming ability, and it cannotradedmicelle of linear PVP loadedwithMTZ (1:1 ratio), D) unloaded star-shaped PVP and
Fig. 4.A-C)DSC thermograms of the studiedpolymer-drugmixtures for A) linear, B) star-shaped and C) commercial PVPs. As the inset in A), DSC thermogramof the neatMTZ is presented.
Heating/cooling rate of performed DSC measurements was equal to 10 K min−1. D) Tg vs weigh a fraction of PVP (x) in the indicated micellar formulations.
R. Bielas, P. Maksym, M. Tarnacka et al. Journal of Molecular Liquids 332 (2021) 115789be supercooled and does not vitrify. Interestingly, DSC curves recorded
for the various polymer-drug mixtures revealed a significantly different
behaviour when compared to the neat MTZ. As observed, all thermo-
grams measured for the examined mixtures exhibit the presence of a
clear heat capacity jumps at low temperatures, related to the glass tran-
sition phenomenon, independently to the applied kind of PVP formula-
tions, see Fig. 4.
Interestingly, Tgs of all types of binary systems are much lower with
respect to neat amorphous PVP, which is characterised by a high Tg (see
Fig. 4D and Table S1 in the SI). As previously mentioned, Tg of linear,6
star-shaped and commercial polymers are Tg = 443 K, Tg = 429 K and
Tg=450 K, respectively. The glass transition temperature of the studied
PVP-API mixture differs significantly with MTZ concentration, where a
strong decrease of Tg of the studied micellar systems indicates a strong
plasticising effect of a drug on the glass transition temperature in binary
systems, see Fig. 4D. It can be clearly seen that for mixtures with high
MTZ content, the influence is very strong, (Tg lower by more than
100 K). On the other hand, in the case of 1:2 polymer-drug mixtures,
the additional exothermal event related to the crystallisation process,
followed by a clear melting, can be observed. Obtained data indicated
R. Bielas, P. Maksym, M. Tarnacka et al. Journal of Molecular Liquids 332 (2021) 115789that MTZ dispersed in the polymermatrix (1:2 weight ratio) is the least
physically stable and tends to crystallise upon heating. Nevertheless, it
should be pointed out that the determined values of Tm of MTZ in the
studied micellar systems are comparable independently to the applied
PVP formulation and are significantly lower when compared to the
neat crystalline API, see the inset in Fig. 4A. One can recall that usually
in the case of binary systems, the decrease of the melting temperature
is often discussed in terms of either strong intermolecular interactions
between both components, size of crystallites, or thepresenceof various
polymorphic forms of API obtained at given conditions.
To verify this hypothesis, we have performed further XRDmeasure-
ments on the produced micelles after approximately one week of stor-
age. As it is shown in Fig. 5A, diffraction patterns for neat PVPs display
broad peaks, typical for amorphous-like structure with no long-range
order. In turn, the sample of commercial MTZ gives diffraction pattern
with Bragg peaks, characteristic for crystalline material. The crystal sys-
temof commercialMTZwas identified asmonoclinic P 21/c space group
with lattice parameters a≈ 7.03, b≈ 8.73, b≈ 12. 82 Å and cell angles
α≈ 90, β≈ 94.5, γ≈ 90° (CCDC number 1212679 in Cambridge Crys-
tallographic Data Centre). In case of all polymer-drug mixtures in 1:2
ratio, one can see that the diffraction patterns are composed of contribu-
tion fromnon-crystalline PVP and crystallineMTZ in the same polymor-
phic form as the commercial reference drug. Moreover, for other
mixtures with higher concentrations of polymer (1:1 and 2:1), we
also observed the crystallisation of MTZ to the same crystal phase (see
Fig. S2 in the SI). The size of crystallites in the direction perpendicular
to the (011) lattice plane, D(011), calculated for the commercial MTZ
using the Scherrer formula [35] (L = Kλ/FWHMcosθ, where the
Scherrer constant K was equal to 0.9, θ is the Bragg angle of the (011)
reflection at around 0.9 Å−1 and FWHM is its full-width at half-
maximum) was 12 ± 1 nm. The widths of Bragg peaks for MTZ in
the mixtures, determined from the diffractograms after subtraction ofFig. 5. A) XRD patterns of the studied neatMTZ, PVP polymers and polymer-drugmixtures in 1
after the sample preparation and after 1 week of storage.
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the contribution from PVP, are very similar to that determined for the
neat drug. Therefore, we can suppose that the sizes of MTZ crystallites
in the mixtures are also on the order of 12 nm. We did not observe
any trend in the behaviour of crystallite size depending on the type
and amount of PVP.
Herein, it can be emphasised that the XRD data showing partial or
full crystallisation of MTZ in micellar systems stay at first sight in con-
trast to the DSC thermograms, which demonstrated that the studied
systemswere amorphous just after preparation. To justify these results,
one can consider that in the systems of lower PVP concentration, there
could be some residual API nuclei, which dissolved in PVP upon heating
in DSC aluminium pans. Therefore, we observed only glass transition
peak on DSC curves and did not detect any signal coming from the
heat of fusion of crystalline API. A better understanding of the discrep-
ancy between results from XRD and DSC brought additional diffraction
measurements just after the preparation of the PVP-MTZ systems. In
Fig. 5B one can clearly see that in the micelles measured 1 h after prep-
aration the degree of crystallinity is much lower and the content of MTZ
in the amorphous form is higher than in the samplemeasured oneweek
after preparation. It suggests that even though produced micellar sys-
tems are completely or partially amorphous just after the preparation,
this state is not stable and MTZ tends to recrystallise very quickly to
the same polymorphic form and size of crystallites as the original refer-
ence API. Having this result in mind, one can claim that the strong de-
pression of the Tg in binary mixtures as well as Tm of MTZ is due to
strong molecular interactions between API and polymer irrespectively
on the source and topology.
As a final point of our investigations, we performed drug release
studies for each considered herein system. As themost optimal, a dialy-
sis method has been chosen for this purpose. Solutions of the obtained
polymer-drug mixtures (c = 2 mg/mL) were placed into the dialysis
membrane bags and then immersed into the PBS pH = 7,4 at 310 K:2 weight ratio. B) XRD patterns of the PVP-MTZmixture in 1:1 weight ratiomeasured just
r-drug ratios. A) Star-shaped PVP, B) linear PVP and C) commercial PVP.
R. Bielas, P. Maksym, M. Tarnacka et al. Journal of Molecular Liquids 332 (2021) 115789what imitates the physiological conditions. Samples were taken in time,
and the obtained results were collected in Fig. 6.
All samples exhibited a burst release of MTZ in the first 5 h of the ex-
periment. After this time, the release slowsdownand reaches up to 90% in
the 30 h, irrespectively of the type of the applied polymer. A clear depen-
dency of release speed on the concentration ofMTZ in the polymermatrix
was shown. All systems exhibited much faster drug release as MTZ con-
centration in the polymer matrix increased. For the star-shaped system
of 1:2 PVPMTZ ratio, which released more than 90% of the drug within
6 h, this relationship is exceptionally clear. Additionally, themathematical
models were fitted to the release process (see the SI, Fig. S3, Table S2). As
expected, none of the tested samples followed the zero-order model. The
model that turned out to describe the results in the bestwaywas thefirst-
order (Ist) approach, which would indicate that the release of MTZ from
the investigated systems is concentration-dependent to the greatest ex-
tent. For some of the proposed mixtures, we additionally found a good
correlationwith theHiguchimodel,whatmight suggest that the diffusion
process also clearly influences the release ofMTZ. Similar resultswere ob-
tained for various delivery systems designed for this drug [14,44], [45].
Taking advantage of fitting dissolution curves to the Ist order kinetics,
we have also determined drug release rate constants. The dependence
of this constant on the PVP concentration in themicellar systemwas pre-
sented (see the SI, Fig. S4). As it turned out, these results also confirmed
that the star-shaped topology influences significantly the MTZ release
rate from the polymermatrix. For both linear and commercial PVP, the re-
lease constantswere basically the same. Thesefindings lead to the conclu-
sion that linear topology of PVP is better suited for sustained drug release
frommicellar systems than the star-shaped one. Systemswith lowerMTZ
content (both 1:1 and 2:1 polymer-drug ratio) showed no significant dif-
ferences in drug release.
4. Conclusions
New PVP-based DDS produced via different synthetic strategy (con-
trolled vs uncontrolled polymerisation) varying in topology, and chain
lengths have been designed for MTZ. After solubilisation on the aqueous
medium, PVP-MTZ mixtures formed micellar structures, what was con-
firmed by TEM analysis. It is worth noting that the micellisation was in-
duced by the presence of the drug, and was not observed for neat
polymers. Both very low ZP and low CMC values suggest that the ob-
tained systems are prone to aggregation due to the concentration
changes. This would be a great explanation of discrepancies in sizes of
matrices hydrodynamic diameters values. Among all micellar systems
explored herein, the linear-based PVP DDS produced via CRP methodol-
ogy showed themost promising features asMTZ nanocarriers. It has also
been shown that mixing of MTZ with PVP significantly reduces the glass
transition temperature of the binary mixture (more than 100 K).
Designed herein, DDS could release MTZ more than 6 h. Our studies
revealed that the burst release effect occurs for all proposed systems,
resulting in the initial release of about 60% of the drug in first 5 h, inde-
pendently of the type of PVP polymer applied. The concentration of the
micellar system in the aqueousmedium and diffusion have been shown
as the main factors influencing the release process. It is anticipated that
results presented herein will advanced design and development of
novel PVP-based DDS of MTZ.
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